Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on September 18, 2026, reporting two sales of common stock on September 16, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • First sale: 5 shares of common stock disposed of at $194.9589 per share on September 16, 2026.
  • Second sale: 336 shares of common stock disposed of at $199.3032 per share on September 16, 2026.
  • Plan purpose: Both transactions were made to satisfy Sandler's tax withholding obligation upon the vesting of restricted stock units, according to the filing.
  • 10b5-1 plan: The sales were executed pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026.
  • Remaining ownership: Following the transactions, Sandler directly beneficially owned 52,868 shares, including 52,350 restricted stock units.
  • ESPP shares: The post-first-sale total of 53,204 shares includes 209 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2026.

Sandler's Share Sales and Beneficial Ownership at Revolution Medicines

According to the Form 4 filing, Alan B. Sandler, serving as Chief Development Officer of Revolution Medicines, Inc., disposed of a total of 341 shares of common stock across two transactions on September 16, 2026. The filing notes that both sales were carried out under a Rule 10b5-1 instruction letter that Sandler adopted on June 13, 2026, specifically to satisfy tax withholding obligations arising from the vesting of restricted stock units.

In the first transaction, 5 shares were sold at a price of $194.9589 per share. Following that sale, the filing reports Sandler's direct beneficial ownership stood at 53,204 shares, a figure that the filing notes includes 209 shares acquired under the issuer's Employee Stock Purchase Plan on May 31, 2026. In the second transaction, 336 shares were sold at $199.3032 per share, reducing direct beneficial ownership to 52,868 shares. The filing discloses that this remaining total includes 52,350 restricted stock units.

The Form 4 was signed by Jack Anders as attorney-in-fact for Alan B. Sandler and dated September 18, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing discloses two open-market sales of Revolution Medicines common stock by Chief Development Officer Alan B. Sandler on September 16, 2026, totaling 341 shares, conducted under a pre-adopted Rule 10b5-1 plan to cover tax withholding on vesting restricted stock units.